United Kingdom · Series B startup
5 rounds we have observed, with the 7 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$67Mraised across 5 rounds since 2010, from 5 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
No investor was named in the report.
Also list them on their own siteFuture Planet Capital
Shares issued, filed with Companies House (SH01); no report of this raise yet
Sofinnova Partners
Astellas Venture Management
EMBL VenturesFrom a historical funding record
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Astellas Venture ManagementSofinnova PartnersImperial Innovations Investment Management
Sofinnova InvestmentsEMBL VenturesRainbow Seed FundAvlar BioVenturesMissing a round, or an investor who was in one? Tell us.
These 3 firms list Crescendo Biologics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.
Crescendo Biologics's investors include Astellas Venture Management, Sofinnova Partners, Imperial Innovations Investment Management, Sofinnova Investments and EMBL Ventures, and 2 more on record.
Crescendo Biologics has raised $67M across 5 rounds since 2010. One round did not disclose an amount, so the total is a floor.
Crescendo Biologics's most recent round was a Series B of $31M in Jan 2022.
Its most recent round, $31M in Jan 2022, is also its largest on record.
Crescendo Biologics's first round on record, in Jan 2010, was backed by Sofinnova Investments, Rainbow Seed Fund and Avlar BioVentures.
Crescendo Biologics's latest named round is a Series B, in Jan 2022.
Crescendo Biologics is based in the United Kingdom.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United Kingdom · 
